Monitoring bypassing agent therapy – a prospective crossover study comparing thromboelastometry and thrombin generation assay
Authors:
- 18 December 2014
- journal article
- Published by Wiley in Haemophilia
- Vol. 21 (2) , 275-283
Abstract
Summary: The aim of this study was to evaluate the capability of thromboelastometry (ROTEM) and thrombin generation assay (TGA) to monitor the treatment response of bypassing agent (BPA) therapy and to study whether one method is superior to another. In a prospective crossover study haemophilia A patients with high titre inhibitors were included to receive a dose of 75 U kg−1 activated prothrombin complex concentrates (aPCC) intravenously. Blood sampling was performed at baseline, 15, 30 min, 1, 2, 3 and 4 h post‐infusion for TGA and ROTEM analysis. After a washout period of 14 days the subjects received recombinant FVIIa (rFVIIa) at a dose of 90 μg kg−1 and similar blood sampling was performed. Healthy subjects were used as controls. Six haemophilia A patients with inhibitors were included. We found that TGA parameters endogenous thrombin potential (ETP) and peak thrombin increased 2–3 folds from baseline 15–30 min after infusion. ROTEM parameters MaxVel and maximum clot firmness increased to a level comparable to that of healthy controls. An individual difference in response was observed for different parameters among participants. ETP and peak thrombin were almost two‐fold greater following aPCC infusion compared to rFVIIa, whereas ROTEM parameters showed no difference in response between the two products. The study showed that ROTEM and TGA have a great potential to evaluate the effect of BPA in haemophilia patients with inhibitors. TGA seemed to be more sensitive than ROTEM in reflecting the difference in treatment response between aPCC and rFVIIa. Additional prospective clinical studies are needed to clarify which assay and what parameters are clinically predictive.Keywords
This publication has 43 references indexed in Scilit:
- Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research articleJournal of Cardiothoracic Surgery, 2013
- Results of the WIRK prospective, non‐interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disordersHaemophilia, 2013
- Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non‐orthopaedic surgeryHaemophilia, 2012
- Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin‐free method] demonstrates efficacy, safety and low‐risk for immunogenicity in routine clinical practiceHaemophilia, 2010
- Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitorsHaemophilia, 2009
- High rate of unprovoked recurrent venous thrombosis is associated with high thrombin‐generating potential in a prospective cohort studyJournal of Thrombosis and Haemostasis, 2008
- Single 270 μg kg−1‐dose rFVIIa vs. standard 90 μg kg−1‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparisonHaemophilia, 2007
- Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastographyHaemophilia, 2006
- Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and BThrombosis and Haemostasis, 2005
- The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIIINew England Journal of Medicine, 1981